Home > Boards > US Listed > Medical - Drugs > Menlo Therapeutics Inc. (MNLO) (MNLO)

Failed phase 2

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
realfast95 Member Profile
Member Level 
Followed By 48
Posts 14,665
Boards Moderated 1
Alias Born 11/29/06
160x600 placeholder
Robbins Geller Rudman & Dowd LLP Announce Proposed Settlement in the Menlo Therapeutics Inc. Securities Settlement Business Wire - 5/22/2020 8:30:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/11/2020 8:04:15 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/11/2020 7:09:14 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/8/2020 5:55:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/8/2020 5:55:34 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/8/2020 5:55:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/8/2020 5:54:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/8/2020 5:54:15 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 5/7/2020 5:28:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/23/2020 4:31:08 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 4/16/2020 12:47:43 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/10/2020 4:01:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/7/2020 5:24:07 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/7/2020 5:23:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/7/2020 5:23:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/7/2020 5:22:54 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/7/2020 5:22:34 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/7/2020 5:22:14 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/7/2020 5:20:33 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/6/2020 9:00:58 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/2/2020 4:48:41 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/2/2020 4:42:42 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/2/2020 4:42:12 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/2/2020 4:33:49 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/25/2020 5:02:11 PM
realfast95 Member Level  Wednesday, 02/26/20 07:37:58 AM
Re: None
Post # of 294 
Failed phase 2


Menlo Therapeutics Announces Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin
February 26, 2020 at 7:30 AM EST
Menlo to Host Conference Call Today at 8:30 AM Eastern Time; Foamix’s CEO David Domzalski will be Available for Q&A

REDWOOD CITY, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced results from its Phase 2 clinical trial evaluating the safety and efficacy of once daily oral serlopitant for the treatment of chronic pruritus (itch) of unknown origin (CPUO). The trial, which included 233 patients, did not meet its primary endpoint to show a statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. In the trial, 37.9% of patients in the serlopitant group (N=116) achieved a 4-point or greater improvement on the worst-itch numeric rating scale, or WI-NRS, at week 10 compared to baseline (primary efficacy endpoint) versus 39.3% of patients treated with placebo (N=117). There were no meaningful differences observed between the serlopitant and placebo groups in the prospectively-defined secondary endpoints.

“We conducted this trial in CPUO in the hope of offering the first-ever approved therapy for patients suffering from severe pruritus associated with this condition,” said Steve Basta, chief executive officer of Menlo Therapeutics. “We were surprised to see a placebo response significantly larger than observed in our prior studies. The higher placebo response rate may be due to characteristics of the CPUO population, which is not well understood clinically.”

The Phase 2 multicenter, placebo-controlled double-blind clinical trial enrolled 233 patients with self-reported CPUO, who experienced pruritus for at least six months prior to enrollment with no identified underlying cause for the pruritus. This trial compared treatment with serlopitant versus placebo for 10 weeks.

Serlopitant was well-tolerated. The frequency of treatment-emergent adverse events assessed as likely related to treatment were 10.3% in the serlopitant group versus 2.6% in the placebo group. The most frequently reported adverse events in the serlopitant group were diarrhea (6.9%), somnolence (5.2%), fatigue and headache (2.6% each). The most frequently reported adverse events in the placebo group were gastroesophageal reflux disease and arthralgia (2.6% each). Two serlopitant-treated subjects reported a total of three serious adverse events which were deemed to not be related to study drug. To date, serlopitant has been administered to over 2,000 individuals, including patients who have received treatment for up to one year.

Results from the company’s Phase 3 trials for the treatment of pruritus associated with prurigo nodularis (PN) are expected in March or April of this year.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist